N. Engl. J. Med.

Osimertinib in EGFR Mutation–Positive Advanced NSCLC.

Related Questions

Is it acceptable to treat patients with limited, asymptomatic brain metastases and EGFR-mutant NSCLC with upfront TKI?

Radiation Oncology · St. Francis Radiation Oncology

Though some clinicians have been exploring the idea of targeted therapy for EGFR mutant brain metastases, this has been done in the absence of strong evidence. Reasons for pushing this idea are that sometimes the lesions seem to respond, and this has been seen in some single arm studies and anecdota...